Table 2.
Clinical details of KD vs. control cases
| KD cases | Control cases | |
|---|---|---|
| (n = 308) | (n = 326) | |
| Age in yearsa | ||
| Median | 6.5 | 6.3 |
| Sex, n (%) | ||
| Female | 114 (37) | 137 (42) |
| Male | 194 (63) | 189 (58) |
| KD diagnosis, n (%) | ||
| Complete | 269 | n.a. |
| Incomplete with laboratory changes b | 15 | n.a. |
| Incomplete with CAA | 24 | n.a. |
| Days until start of IVIG therapy | ||
| Average | 6.6 | n.a. |
| Min – max | 0–32 | n.a. |
| Refractory to IVIG treatment c | ||
| Yes > 1 IVIG cycle | 29 (13.4%) | n.a. |
| Therapy with steroids, n (%) | ||
| Yes, for KD treatment | 53 (17.2) | n.a. |
| Yes, for other reasons | 9 (2.9) | n.a. |
| CAA in acute phase, n (%) | ||
| Yes | 36 (11.6) | n.a. |
| CAA after one year c, n (%) | ||
| Yes | 13 (5.9) | n.a. |
aat the end of the case-control study survey (i.e, March 22, 2017)
b according to the guidelines of the American Heart Association at least three other abnormal supplemental laboratory findings, namely (1) increased alanine transaminase, (2) albumin ≤3.0 g/dL, (3) leukocyturia, (4) anaemia for age, (5) leukocytosis (≥15,000/mm3) (6) thrombocytosis (≥450,000/mm3) [16]
cfor cases reported in 2013/2014 n = 217; CAA = coronary artery aneurysma; n.a. = not applicable